Clinical Trial Update: Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating aprepitant for nausea and vomiting induced by chemoradiotherapy in head and neck cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Aprepitant (aprepitant)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Vomiting, Nausea Post Chemotherapy | Phase 2 | Status: COMPLETED